The global market for multiple sclerosis drugs is expected to reach $XX billion by 2023, according to a new report by Reportlinker.com. The major players in this market are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer Inc., Merck & Co. Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, Acorda Therapeutics Inc.
The multiple sclerosis drugs market is expected to grow at a CAGR of XX% over the next five years. The growth of this market is being driven by the increasing prevalence of multiple sclerosis, the launch of new drugs, and the growing demand for combination therapies.
The report “Multiple Sclerosis Drugs Global Market Report 2023” provides a comprehensive overview of the global multiple sclerosis drugs market. It provides information on the market size and forecast.
The global multiple sclerosis drugs market is expected to grow from $24.75 billion in 2021 to $26.29 billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods.